Cargando…

Effectiveness and Safety of Lianhua Qingwen Capsules for COVID-19: A Propensity-Score Matched Cohort Study

As a traditional Chinese medicine, Lianhua Qingwen capsules have been widely used to treat Coronavirus Disease 2019 (COVID-19). This study was aimed to demonstrate the association between treatment with Lianhua Qingwen capsules and the clinical outcomes of hospitalized patients with COVID-19. This r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yun, Zhang, Meng, Yang, Qing-qing, Li, Wen-jing, Yang, Kun, Hu, Wen, Gao, Su-yu, Jiang, Qiao-li, Lin, Li-kai, Cheng, Hong, Sun, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957644/ https://www.ncbi.nlm.nih.gov/pubmed/36846053 http://dx.doi.org/10.1155/2023/6028554

Ejemplares similares

Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study
por: Xu, Xiangru, et al.
Publicado: (2023)

The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule
por: Shen, Xuhui, et al.
Publicado: (2021)

Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule
por: Lan, Xiao-fang, et al.
Publicado: (2021)

Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis
por: Li, Yapeng, et al.
Publicado: (2022)

Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis
por: Sun, Xiao-hu, et al.
Publicado: (2022)

Qualitative and Quantitative Analysis of the Major Constituents in Chinese Medical Preparation Lianhua-Qingwen Capsule by UPLC-DAD-QTOF-MS
por: Jia, Weina, et al.
Publicado: (2015)

The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis
por: Hu, Caiyun, et al.
Publicado: (2022)

Screening for Anti-Inflammation Quality Markers of Lianhua Qingwen Capsule Based on Network Pharmacology, UPLC, and Biological Activity
por: Zhou, Yongfeng, et al.
Publicado: (2021)

Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects
por: Li, Liu-Cheng, et al.
Publicado: (2020)

An umbrella review of Lianhua Qingwen combined with Western medicine for the treatment of coronavirus disease 2019
por: Yang, Kelu, et al.
Publicado: (2022)

Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019
por: Wang, Deng-chao, et al.
Publicado: (2022)

Predicting for anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of Lianhua Qingwen Capsules in treating COVID-19
por: Hong, Liang, et al.
Publicado: (2022)

Qualitative analysis of chemical components in Lianhua Qingwen capsule by HPLC-Q Exactive-Orbitrap-MS coupled with GC-MS
por: Fu, Shuai, et al.
Publicado: (2021)

Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs
por: CHEN, Yuanyuan, et al.
Publicado: (2023)

Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID‐19
por: Xia, Qi‐Dong, et al.
Publicado: (2020)

Lianhua Qingwen Capsules Reduced the Rate of Severity in Patients with COVID-19: A System Review and Meta-Analysis of Randomized Controlled Trials
por: Shi, Chengqian, et al.
Publicado: (2022)

Effect of Lianhua Qingwen capsules on the positive rate of COVID-19 close contacts: A retrospective analysis of a large-scale population-based cohort study
por: Qiao, Yunfeng, et al.
Publicado: (2023)

Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial
por: Zhan, Yang-Qing, et al.
Publicado: (2023)

Efficacy and safety of Lianhua Qingwen in the treatment of patients with moderate COVID-19 infection: A protocol for systematic review and meta analysis
por: Liu, Nanyang, et al.
Publicado: (2020)

Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial
por: Xiao, Mingzhong, et al.
Publicado: (2020)

A meta-analysis for Lianhua Qingwen on the treatment of Coronavirus disease 2019 (COVID-19)
por: Zhuang, Jieqin, et al.
Publicado: (2021)

Mechanisms Underlying the Effects of Lianhua Qingwen on Sepsis-Induced Acute Lung Injury: A Network Pharmacology Approach
por: Yang, Ruhao, et al.
Publicado: (2021)

Lianhua-Qingwen Displays Antiviral and Anti-Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model
por: Yang, Chunguang, et al.
Publicado: (2020)

Intestinal microbiota analysis and network pharmacology reveal the mechanism by which Lianhua Qingwen capsule improves the immune function of mice infected with influenza A virus
por: Xu, Ping, et al.
Publicado: (2022)

Efficacy and safety of Lianhua Qingwen capsules, a repurposed Chinese herb, in patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [Phytomedicine 85 (2021) 153242]
por: Hu, Ke, et al.
Publicado: (2022)

The efficacy and safety of Lianhua Qingwen (LHQW) for coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis
por: Zhang, Qiongshuai, et al.
Publicado: (2020)

Establishment of an anti-inflammation-based bioassay for the quality control of the 13-component TCM formula (Lianhua Qingwen)
por: Chen, Shuaishuai, et al.
Publicado: (2021)

Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19
por: Li, Liyuan, et al.
Publicado: (2022)

Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis
por: Hu, Caiyun, et al.
Publicado: (2020)

Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019(COVID-19): Meta-analysis of randomized controlled trials
por: Zeng, Mengjie, et al.
Publicado: (2020)

A Meta-Analysis of 13 Randomized Trials on Traditional Chinese Medicine as Adjunctive Therapy for COVID-19: Novel Insights into Lianhua Qingwen
por: Lei, Yi, et al.
Publicado: (2022)

Traditional Chinese medicine Lianhua Qingwen for treating COVID-19: A protocol for a meta-analysis and systematic review of randomized controlled trials
por: Li, Shasha, et al.
Publicado: (2021)

Exploration of the Mechanism of Lianhua Qingwen in Treating Influenza Virus Pneumonia and New Coronavirus Pneumonia with the Concept of “Different Diseases with the Same Treatment” Based on Network Pharmacology
por: Su, Huihui, et al.
Publicado: (2022)

Molecular docking and molecular dynamics study Lianhua Qingwen granules (LHQW) treats COVID-19 by inhibiting inflammatory response and regulating cell survival
por: Cao, Jun-Feng, et al.
Publicado: (2022)

Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis
por: Zhang, Xiaolin, et al.
Publicado: (2020)

Identification of a Pharmacological Biomarker for the Bioassay-Based Quality Control of a Thirteen-Component TCM Formula (Lianhua Qingwen) Used in Treating Influenza A Virus (H1N1) Infection
por: Gao, Dan, et al.
Publicado: (2020)

Peritoneal dialysis outcomes in patients with nephrotic syndrome: a propensity score-matched cohort study
por: Zhou, Si-Jia, et al.
Publicado: (2020)

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023)

Bioactive Components from Qingwen Baidu Decoction against LPS-Induced Acute Lung Injury in Rats
por: Zhang, Qi, et al.
Publicado: (2017)

Decreased Serum C3 Levels in Immunoglobulin A (IgA) Nephropathy with Chronic Kidney Disease: A Propensity Score Matching Study
por: Yang, Xi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7a4st548qq02le5fg0c522fdm8